White Paper From Molecule to Market: Autonomous Life Sciences Operations Why the most critical workflows in Life Sciences need orchestration, not more tools Oskari Pennanen Vishal Mehta White Paper 2 Life Sciences companies are racing to get therapies to patients. Meeting that challenge means running trials faster, launching more drugs, and scaling across more markets, while maintaining regulatory compliance and controlling costs. Science has never moved faster, thanks to AI. However, companies face a paradox. AI-accelerated discovery delivers breakthroughs faster, but equipment downtime still delays experiments. Patient recruitment systems find candidates faster, but site onboarding and activation still take months. Manufacturing equipment runs batch after batch, while production losses remain invisible. Companies have the ambition but not the operational infrastructure to support it. The stakes are quantifiable